Nasdaq Biotechnology Ishares (IBB) 342.36 $IBB
ISIS Pharmaceuticals Has The Cash To Develop Its Expanding Product Pipeline
Emerging Equities - at Seeking Alpha - Fri Mar 06, 4:03PM CST
BIIB: 417.63 (-7.98), ISIS: 70.44 (-1.32), IBB: 342.36 (-5.31), GSK: 46.73 (-0.87), ETF: 12.82 (-0.18)
IBB Doesn't Fit The Mantra Of High-Risk High-Reward
Noah Kiedrowski - at Seeking Alpha - Fri Mar 06, 2:03PM CST
IBB: 342.36 (-5.31)
Gilead, Mylan, And J&J: Cheap Compared To Peers
Hedgephone - at Seeking Alpha - Fri Mar 06, 11:32AM CST
JNJ: 100.11 (-2.41), GILD: 101.81 (-1.61), IBB: 342.36 (-5.31), MYL: 55.44 (-1.25)
Either Way - The U.S. Is In Trouble
Individual Trader - at Seeking Alpha - Thu Mar 05, 1:24AM CST
SPY: 207.50 (-2.96), IBB: 342.36 (-5.31), UUP: 25.80 (+0.31), TLT: 123.50 (-2.79)
SBIO Vs. BBC: 2 Innovative Biotech ETFs Head-To-Head - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 11:17AM CST
These newly launched products provide exposure to clinical biotechnology companies and have produced decent gains in the year-to-date frame.
SBIO: 29.86 (-0.22), BBC: 32.80 (-0.46), IBB: 342.36 (-5.31)
NASDAQ Hits 5,000: Does The IPO Market Suggest A Biotech Bubble?
Renaissance Capital IPO Research - Seeking Alpha - Tue Mar 03, 8:07AM CST
The NASDAQ Composite is fast approaching its all-time high from March 2000. On Monday it reached 5,000 for the first time since the tech bubble. Today's technology IPOs look much tamer in number than they did 15 years ago, but a boom in biotech...
QQQ: 107.41 (-1.23), XBI: 224.72 (-2.85), IBB: 342.36 (-5.31)
In 2015, Little Is The New Big
Nicholas Vardy - Seeking Alpha - Tue Mar 03, 12:40AM CST
Editor's note: Originally published on 24 February, 2015 When it comes to stocks, “big” is sometimes little — and “little” is sometimes big. Here I’m referring here to the recent performance of small-cap stocks...
RWJ: 56.85 (-0.81), IJT: 125.46 (-1.81), IJS: 116.10 (-1.50), IJR: 114.60 (-1.60), SBB: 51.99 (+0.98), VIOO: 103.03 (-1.59), SLY: 105.10 (-1.68), SAA: 114.70 (-2.40), SDD: 38.25 (+0.76), FYX: 49.12 (-0.80), SCHA: 56.29 (-0.72), IBB: 342.36 (-5.31), ZSML: 26.49 (-0.32), VIOV: 99.91 (-1.14), SLYV: 104.52 (-1.42), RSCO: 85.80 (-1.20), RZV: 62.67 (-0.73), VB: 119.20 (-1.54), JKJ: 139.58 (-1.81), IWM: 121.17 (-1.55), VIOG: 107.25 (-1.62), SLYG: 182.09 (-2.75), RZG: 84.40 (-1.16)
Investors Are Best To Avoid The IShares Nasdaq Biotechnology ETF
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 9:24AM CST
JNJ: 100.11 (-2.41), BIIB: 417.63 (-7.98), ACAD: 38.94 (-0.32), SPY: 207.50 (-2.96), PCYC: 254.56 (+0.34), GILD: 101.81 (-1.61), MRK: 56.84 (-1.14), ALXN: 181.65 (-4.14), IBB: 342.36 (-5.31), CELG: 118.03 (-2.68)
All That Cash
Derek Lowe - Seeking Alpha - Wed Feb 25, 1:12PM CST
From the LifeSciVC blog, here's a revealing comparison of the amount of money going into startups in this business. This is why I tend to get worked up about the number of stock buyback plans among the big pharma players. It would seem that...
XBI: 224.72 (-2.85), IBB: 342.36 (-5.31)
Manipulated Markets And How We Invest In Them
Individual Trader - at Seeking Alpha - Tue Feb 24, 6:06AM CST
SPY: 207.50 (-2.96), IBB: 342.36 (-5.31)
Biotech Weekly: 5 Factors Contributing To The Crazy Week That Was In Small Cap Biotech
Daniel Ward - at Seeking Alpha - Mon Feb 23, 7:40AM CST
HEB: 0.25 (-0.01), XBI: 224.72 (-2.85), IBIO: 0.81 (-0.03), IBB: 342.36 (-5.31), SPPI: 6.26 (+0.02), CLTX: 0.91 (-0.02)
Top Funds' Activity In Q4 2014
Leo Kolivakis - Seeking Alpha - Fri Feb 20, 2:04PM CST
Svea Herbst-Bayliss and Sam Forgione of Reuters report, Top U.S. hedge funds cut Apple stakes ahead of all-time high : Top U.S. hedge fund management firms, including David Einhorn's Greenlight Capital and Philippe Laffont's Coatue Management,...
HK: 1.77 (-0.18), XLB: 50.46 (-0.69), GREK: 11.82 (-0.56), XBI: 224.72 (-2.85), IBB: 342.36 (-5.31), NBG: 1.43 (-0.08), RRC: 48.75 (-1.01), RIG: 15.52 (-0.48), XLK: 42.39 (-0.53), SPR: 49.11 (-0.52), TWTR: 46.75 (-0.60), AAPL: 126.60 (+0.19), CSCO: 28.92 (-0.38), BHI: 60.92 (-1.18), XLE: 76.78 (-1.40), DVN: 59.18 (-1.65), FEYE: 42.83 (-1.08), XEC: 109.44 (-1.66), GSG: 20.44 (-0.25), NFLX: 454.12 (-13.53), GENE: 4.86 (-1.39), ROSG: 3.24 (-0.04), SBIO: 29.86 (-0.22), QQQ: 107.41 (-1.23), IDRA: 4.68 (-0.21), IWM: 121.17 (-1.55), BABA: 84.40 (-1.70)
These Stocks Are Steamrolling Everything in their Path…
Greg Guenthner - Daily Reckoning - Thu Feb 19, 8:24AM CST
This post These Stocks Are Steamrolling Everything in their Path… appeared first on Daily Reckoning . Today you’re hopping on a good ole fashioned steamroller for an honest day’s pay. Your job is to turn every underperforming industry and...
IBB: 342.36 (-5.31)
Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 1.04% Rise
Comtex SmarTrend(R) - Tue Feb 17, 4:05PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $322.73 to a high of $327.24. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $323.55 on volume of 882,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 342.36 (-5.31)
iShares Nasdaq Biotechnology Index Rises 1.04% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Feb 17, 4:04PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $322.73 to a high of $327.24. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $323.55 on volume of 882,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 342.36 (-5.31)
Pharma And Biotech Funds Add Zest To Your Portfolio
John Dowdee - at Seeking Alpha - Fri Feb 13, 7:10AM CST
PBE: 55.37 (-0.90), HQL: 28.00 (-0.26), FBT: 118.67 (-1.54), PJP: 75.85 (-1.25), XBI: 224.72 (-2.85), XPH: 123.87 (-1.47), IBB: 342.36 (-5.31), HQH: 35.27 (-0.44)
On The Cusp Of Raising Rates?
Leo Kolivakis - Seeking Alpha - Fri Feb 06, 12:59PM CST
Lucia Mutikani of Reuters reports, Strong U.S. job, wage gains open door to mid-year rate hike : U.S. job growth rose solidly in January and wages rebounded strongly, a show of underlying strength in the economy that puts a mid-year interest rate...
XLB: 50.46 (-0.69), QQQ: 107.41 (-1.23), XBI: 224.72 (-2.85), IBB: 342.36 (-5.31), XLK: 42.39 (-0.53), IWM: 121.17 (-1.55), TWTR: 46.75 (-0.60), XLU: 43.39 (-1.34), XLV: 71.41 (-1.43), GSG: 20.44 (-0.25), XLE: 76.78 (-1.40)
Gilead, Amgen Q4 Earnings And Weak Outlook Affect Biotech ETFs
Zacks Funds - Seeking Alpha - Fri Feb 06, 6:17AM CST
The biotech sector stood out last year and the NASDAQ Biotechnology Index delivered a stellar 34% return for 2014. Despite some temporary glitches and rough trading in between, encouraging industry trends, increasing merger and acquisition...
PBE: 55.37 (-0.90), BIIB: 417.63 (-7.98), GILD: 101.81 (-1.61), ALXN: 181.65 (-4.14), BBH: 130.03 (-2.40), IBB: 342.36 (-5.31), AMGN: 154.88 (-4.72)
Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 1:01AM CST
Concerns about pricing pressure are weighing on the overall performance of the biotech sector putting these ETFs in focus.
PBE: 55.37 (-0.90), BIIB: 417.63 (-7.98), GILD: 101.81 (-1.61), ALXN: 181.65 (-4.14), BBH: 130.03 (-2.40), IBB: 342.36 (-5.31), AMGN: 154.88 (-4.72)
ISIS Pharmaceuticals Has The Cash To Develop Its Expanding Product Pipeline
Emerging Equities - at Seeking Alpha - Fri Mar 06, 4:03PM CST
BIIB: 417.63 (-7.98), ISIS: 70.44 (-1.32), IBB: 342.36 (-5.31), GSK: 46.73 (-0.87), ETF: 12.82 (-0.18)
IBB Doesn't Fit The Mantra Of High-Risk High-Reward
Noah Kiedrowski - at Seeking Alpha - Fri Mar 06, 2:03PM CST
IBB: 342.36 (-5.31)
Gilead, Mylan, And J&J: Cheap Compared To Peers
Hedgephone - at Seeking Alpha - Fri Mar 06, 11:32AM CST
JNJ: 100.11 (-2.41), GILD: 101.81 (-1.61), IBB: 342.36 (-5.31), MYL: 55.44 (-1.25)
Either Way - The U.S. Is In Trouble
Individual Trader - at Seeking Alpha - Thu Mar 05, 1:24AM CST
SPY: 207.50 (-2.96), IBB: 342.36 (-5.31), UUP: 25.80 (+0.31), TLT: 123.50 (-2.79)
SBIO Vs. BBC: 2 Innovative Biotech ETFs Head-To-Head - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 11:17AM CST
These newly launched products provide exposure to clinical biotechnology companies and have produced decent gains in the year-to-date frame.
SBIO: 29.86 (-0.22), BBC: 32.80 (-0.46), IBB: 342.36 (-5.31)
NASDAQ Hits 5,000: Does The IPO Market Suggest A Biotech Bubble?
Renaissance Capital IPO Research - Seeking Alpha - Tue Mar 03, 8:07AM CST
The NASDAQ Composite is fast approaching its all-time high from March 2000. On Monday it reached 5,000 for the first time since the tech bubble. Today's technology IPOs look much tamer in number than they did 15 years ago, but a boom in biotech...
QQQ: 107.41 (-1.23), XBI: 224.72 (-2.85), IBB: 342.36 (-5.31)
In 2015, Little Is The New Big
Nicholas Vardy - Seeking Alpha - Tue Mar 03, 12:40AM CST
Editor's note: Originally published on 24 February, 2015 When it comes to stocks, “big” is sometimes little — and “little” is sometimes big. Here I’m referring here to the recent performance of small-cap stocks...
RWJ: 56.85 (-0.81), IJT: 125.46 (-1.81), IJS: 116.10 (-1.50), IJR: 114.60 (-1.60), SBB: 51.99 (+0.98), VIOO: 103.03 (-1.59), SLY: 105.10 (-1.68), SAA: 114.70 (-2.40), SDD: 38.25 (+0.76), FYX: 49.12 (-0.80), SCHA: 56.29 (-0.72), IBB: 342.36 (-5.31), ZSML: 26.49 (-0.32), VIOV: 99.91 (-1.14), SLYV: 104.52 (-1.42), RSCO: 85.80 (-1.20), RZV: 62.67 (-0.73), VB: 119.20 (-1.54), JKJ: 139.58 (-1.81), IWM: 121.17 (-1.55), VIOG: 107.25 (-1.62), SLYG: 182.09 (-2.75), RZG: 84.40 (-1.16)
Investors Are Best To Avoid The IShares Nasdaq Biotechnology ETF
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 9:24AM CST
JNJ: 100.11 (-2.41), BIIB: 417.63 (-7.98), ACAD: 38.94 (-0.32), SPY: 207.50 (-2.96), PCYC: 254.56 (+0.34), GILD: 101.81 (-1.61), MRK: 56.84 (-1.14), ALXN: 181.65 (-4.14), IBB: 342.36 (-5.31), CELG: 118.03 (-2.68)
All That Cash
Derek Lowe - Seeking Alpha - Wed Feb 25, 1:12PM CST
From the LifeSciVC blog, here's a revealing comparison of the amount of money going into startups in this business. This is why I tend to get worked up about the number of stock buyback plans among the big pharma players. It would seem that...
XBI: 224.72 (-2.85), IBB: 342.36 (-5.31)
Manipulated Markets And How We Invest In Them
Individual Trader - at Seeking Alpha - Tue Feb 24, 6:06AM CST
SPY: 207.50 (-2.96), IBB: 342.36 (-5.31)
Biotech Weekly: 5 Factors Contributing To The Crazy Week That Was In Small Cap Biotech
Daniel Ward - at Seeking Alpha - Mon Feb 23, 7:40AM CST
HEB: 0.25 (-0.01), XBI: 224.72 (-2.85), IBIO: 0.81 (-0.03), IBB: 342.36 (-5.31), SPPI: 6.26 (+0.02), CLTX: 0.91 (-0.02)
Top Funds' Activity In Q4 2014
Leo Kolivakis - Seeking Alpha - Fri Feb 20, 2:04PM CST
Svea Herbst-Bayliss and Sam Forgione of Reuters report, Top U.S. hedge funds cut Apple stakes ahead of all-time high : Top U.S. hedge fund management firms, including David Einhorn's Greenlight Capital and Philippe Laffont's Coatue Management,...
HK: 1.77 (-0.18), XLB: 50.46 (-0.69), GREK: 11.82 (-0.56), XBI: 224.72 (-2.85), IBB: 342.36 (-5.31), NBG: 1.43 (-0.08), RRC: 48.75 (-1.01), RIG: 15.52 (-0.48), XLK: 42.39 (-0.53), SPR: 49.11 (-0.52), TWTR: 46.75 (-0.60), AAPL: 126.60 (+0.19), CSCO: 28.92 (-0.38), BHI: 60.92 (-1.18), XLE: 76.78 (-1.40), DVN: 59.18 (-1.65), FEYE: 42.83 (-1.08), XEC: 109.44 (-1.66), GSG: 20.44 (-0.25), NFLX: 454.12 (-13.53), GENE: 4.86 (-1.39), ROSG: 3.24 (-0.04), SBIO: 29.86 (-0.22), QQQ: 107.41 (-1.23), IDRA: 4.68 (-0.21), IWM: 121.17 (-1.55), BABA: 84.40 (-1.70)
These Stocks Are Steamrolling Everything in their Path…
Greg Guenthner - Daily Reckoning - Thu Feb 19, 8:24AM CST
This post These Stocks Are Steamrolling Everything in their Path… appeared first on Daily Reckoning . Today you’re hopping on a good ole fashioned steamroller for an honest day’s pay. Your job is to turn every underperforming industry and...
IBB: 342.36 (-5.31)
Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 1.04% Rise
Comtex SmarTrend(R) - Tue Feb 17, 4:05PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $322.73 to a high of $327.24. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $323.55 on volume of 882,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 342.36 (-5.31)
iShares Nasdaq Biotechnology Index Rises 1.04% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Feb 17, 4:04PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $322.73 to a high of $327.24. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $323.55 on volume of 882,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IBB: 342.36 (-5.31)
Pharma And Biotech Funds Add Zest To Your Portfolio
John Dowdee - at Seeking Alpha - Fri Feb 13, 7:10AM CST
PBE: 55.37 (-0.90), HQL: 28.00 (-0.26), FBT: 118.67 (-1.54), PJP: 75.85 (-1.25), XBI: 224.72 (-2.85), XPH: 123.87 (-1.47), IBB: 342.36 (-5.31), HQH: 35.27 (-0.44)
On The Cusp Of Raising Rates?
Leo Kolivakis - Seeking Alpha - Fri Feb 06, 12:59PM CST
Lucia Mutikani of Reuters reports, Strong U.S. job, wage gains open door to mid-year rate hike : U.S. job growth rose solidly in January and wages rebounded strongly, a show of underlying strength in the economy that puts a mid-year interest rate...
XLB: 50.46 (-0.69), QQQ: 107.41 (-1.23), XBI: 224.72 (-2.85), IBB: 342.36 (-5.31), XLK: 42.39 (-0.53), IWM: 121.17 (-1.55), TWTR: 46.75 (-0.60), XLU: 43.39 (-1.34), XLV: 71.41 (-1.43), GSG: 20.44 (-0.25), XLE: 76.78 (-1.40)
Gilead, Amgen Q4 Earnings And Weak Outlook Affect Biotech ETFs
Zacks Funds - Seeking Alpha - Fri Feb 06, 6:17AM CST
The biotech sector stood out last year and the NASDAQ Biotechnology Index delivered a stellar 34% return for 2014. Despite some temporary glitches and rough trading in between, encouraging industry trends, increasing merger and acquisition...
PBE: 55.37 (-0.90), BIIB: 417.63 (-7.98), GILD: 101.81 (-1.61), ALXN: 181.65 (-4.14), BBH: 130.03 (-2.40), IBB: 342.36 (-5.31), AMGN: 154.88 (-4.72)
Gilead, Amgen Q4 Earnings & Weak Outlook Affect Biotech ETFs - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 1:01AM CST
Concerns about pricing pressure are weighing on the overall performance of the biotech sector putting these ETFs in focus.
PBE: 55.37 (-0.90), BIIB: 417.63 (-7.98), GILD: 101.81 (-1.61), ALXN: 181.65 (-4.14), BBH: 130.03 (-2.40), IBB: 342.36 (-5.31), AMGN: 154.88 (-4.72)
